Related Experiment Video
Updated: Jul 28, 2026
A Preclinical Murine Model of Hepatic Metastases
Published on: September 27, 2014
PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model
Abstract:
Because malignant cells have altered, usually accelerated, energy consumption, targeting metabolic signaling represents a prevailing strategy for tumor therapy. Phosphoinositide-dependent kinase 1 (PDK1) is a proximal signaling molecule of phosphatidylinositol 3-kinase, which is required for metabolic activation. It is still lacking definitive evidence whether inactivation of PDK1 can overwhelm tumorigenesis in vivo. Herein we revealed that mammary-specific ablation of PDK1 could delay tumor initiation, progression and metastasis in a spontaneous mouse tumor model. We also demonstrated that inducible deletion of PDK1 could noticeably shrink the growing breast tumors. However, a small portion of PDK1-deficient tumorigenic cells eventually established tumor lesions, albeit at a relatively later phase, most likely owing to compensatory upregulation of extracellular signal-regulated kinase 1/2 (Erk1/2) phosphorylation. Consequently, simultaneous inhibition of PDK1 and Erk1/2 impeded the survival of breast cancer cells. Thus we identify PDK1 as a potential therapeutic target for breast cancer, particularly in combination with an Erk1/2 inhibitor.
Insights
Targeting phosphoinositide-dependent kinase 1 (PDK1) delays breast cancer growth and metastasis in mice. Combined inhibition of PDK1 and extracellular signal-regulated kinase 1/2 (Erk1/2) shows promise for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Malignant cells exhibit altered energy metabolism, making metabolic signaling a key therapeutic target.
- Phosphoinositide-dependent kinase 1 (PDK1), downstream of phosphatidylinositol 3-kinase, is crucial for metabolic activation in cancer.
- The in vivo efficacy of PDK1 inactivation in suppressing tumorigenesis requires further investigation.
Purpose of the Study:
- To investigate the role of PDK1 in breast cancer initiation, progression, and metastasis using a mouse model.
- To evaluate the therapeutic potential of PDK1 inhibition in established breast tumors.
- To explore compensatory signaling pathways and potential combination therapies for breast cancer.
Main Methods:
- Mammary-specific ablation of PDK1 in a spontaneous mouse tumor model.
- Inducible deletion of PDK1 to assess tumor shrinkage.
- Analysis of extracellular signal-regulated kinase 1/2 (Erk1/2) phosphorylation as a compensatory mechanism.
- Assessment of combined PDK1 and Erk1/2 inhibition on cancer cell survival.
Main Results:
- Mammary-specific PDK1 ablation significantly delayed tumor initiation, progression, and metastasis.
- Inducible deletion of PDK1 led to noticeable shrinkage of established breast tumors.
- Compensatory upregulation of Erk1/2 phosphorylation was observed in some PDK1-deficient cells, enabling tumor recurrence.
- Simultaneous inhibition of PDK1 and Erk1/2 effectively impeded breast cancer cell survival.
Conclusions:
- PDK1 is a critical mediator of breast cancer progression and a potential therapeutic target.
- Targeting PDK1, especially in combination with Erk1/2 inhibitors, offers a promising strategy for breast cancer treatment.
- Understanding compensatory signaling pathways is essential for developing effective combination cancer therapies.
Related Concept Videos
02:23Abnormal Proliferation
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...